Puma Biotechnology

December 17, 2018 - Puma Biotechnology Announces Top Line Results of the Phase III NALA trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer
Read

December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

December 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium
Read

December 3, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

November 7, 2018 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

November 1, 2018 - Puma Biotechnology Reports Third Quarter 2018 Financial Results
Read

October 18, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

October 10, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

October 2, 2018 - Puma Biotechnology’s Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China
Read

September 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference
Read

September 6, 2018 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

September 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology’s NERLYNX® (neratinib) for Extended Adjuvant treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer
Read

August 9, 2018 - Puma Biotechnology Reports Second Quarter 2018 Financial Results
Read

July 31, 2018 - Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada
Read

July 26, 2018 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

July 17, 2018 - Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT trial)
Read

June 29, 2018 - Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer
Read

June 26, 2018 - Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer
Read

June 2, 2018 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 trial of PB272 in Combination with trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting
Read

May 30, 2018 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference
Read

May 9, 2018 - Puma Biotechnology Reports First Quarter 2018 Financial Results
Read

May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018
Read

April 25, 2018 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

April 3, 2018 - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Read

April 2, 2018 - NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination with Capecitabine or Paclitaxel as treatment Options for Patients with Breast Cancer Brain Metastases
Read

March 6, 2018 - Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference
Read

March 1, 2018 - Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
Read

February 23, 2018 - Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer
Read

February 15, 2018 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read

February 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
Read

February 1, 2018 - Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China
Read

January 31, 2018 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers - Data published online today in Nature -
Read

January 30, 2018 - Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel
Read

January 29, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

January 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer
Read

2018 News Releases